Identification of immunodominant epitopes in envelope glycoprotein of human T Lymphotropic virus type II

Renu B. Lal, Donna L. Rudolph, Jonathan E. Kaplan, Brian Hjelle, Paul H. Levine, John E. Coligan, Raphael P Viscidi

Research output: Contribution to journalArticle

Abstract

A series of synthetic peptides derived from the envelope glycoprotein of human T lymphotropic virus type II (HTLV-II) was used in an enzyme immunoassay to determine the immunodominant epitopes of envelope glycoprotein. Of the 11 synthetic peptides spanning the external glycoprotein of HTLV-II (gp52) and the 3 from the transmembrane protein (gp21), 3 peptides from gp52 (termed Env-2085-102. Env-20-209, and Env-20173-256) reacted with most of the polymerase chain reaction-confirmed HTLV-II specimens (83, 95, and 76%, respectively); all other peptides reacted minimally with these specimens. Env-20173-209 reacted with a greater percentage (91 to 100%) of specimens from different risk groups, including intravenous drug users (n = 30), North American Indians (n = 13), Guaymi Indians from Panama (n = 22), and routine U.S. blood donors (n = 34), when compared with Env-2085-102 (73 to 100%) or Env-203219-256 (68 to 83%). Furthermore, Env-2085-102 and Env-202172-209 had some reactivity (8-25%) with serafrom HTLV-I-infected individuals, whereas Env-20219-256 reacted with 58% of HTLV-I specimens. We conclude that peptides Env-2085-102 and Env-202173-209 represent the type-specific immunodominant epitopes of HTLV-II external glycoprotein.

Original languageEnglish (US)
Pages (from-to)274-279
Number of pages6
JournalVirology
Volume186
Issue number1
DOIs
StatePublished - 1992

Fingerprint

Human T-lymphotropic virus 2
Immunodominant Epitopes
Glycoproteins
Peptides
Human T-lymphotropic virus 1
Panama
North American Indians
Drug Users
Blood Donors
Immunoenzyme Techniques
Polymerase Chain Reaction
Proteins

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases

Cite this

Identification of immunodominant epitopes in envelope glycoprotein of human T Lymphotropic virus type II. / Lal, Renu B.; Rudolph, Donna L.; Kaplan, Jonathan E.; Hjelle, Brian; Levine, Paul H.; Coligan, John E.; Viscidi, Raphael P.

In: Virology, Vol. 186, No. 1, 1992, p. 274-279.

Research output: Contribution to journalArticle

Lal, Renu B. ; Rudolph, Donna L. ; Kaplan, Jonathan E. ; Hjelle, Brian ; Levine, Paul H. ; Coligan, John E. ; Viscidi, Raphael P. / Identification of immunodominant epitopes in envelope glycoprotein of human T Lymphotropic virus type II. In: Virology. 1992 ; Vol. 186, No. 1. pp. 274-279.
@article{a8d89cd4a66143dcb06da0b63f9291c6,
title = "Identification of immunodominant epitopes in envelope glycoprotein of human T Lymphotropic virus type II",
abstract = "A series of synthetic peptides derived from the envelope glycoprotein of human T lymphotropic virus type II (HTLV-II) was used in an enzyme immunoassay to determine the immunodominant epitopes of envelope glycoprotein. Of the 11 synthetic peptides spanning the external glycoprotein of HTLV-II (gp52) and the 3 from the transmembrane protein (gp21), 3 peptides from gp52 (termed Env-2085-102. Env-20-209, and Env-20173-256) reacted with most of the polymerase chain reaction-confirmed HTLV-II specimens (83, 95, and 76{\%}, respectively); all other peptides reacted minimally with these specimens. Env-20173-209 reacted with a greater percentage (91 to 100{\%}) of specimens from different risk groups, including intravenous drug users (n = 30), North American Indians (n = 13), Guaymi Indians from Panama (n = 22), and routine U.S. blood donors (n = 34), when compared with Env-2085-102 (73 to 100{\%}) or Env-203219-256 (68 to 83{\%}). Furthermore, Env-2085-102 and Env-202172-209 had some reactivity (8-25{\%}) with serafrom HTLV-I-infected individuals, whereas Env-20219-256 reacted with 58{\%} of HTLV-I specimens. We conclude that peptides Env-2085-102 and Env-202173-209 represent the type-specific immunodominant epitopes of HTLV-II external glycoprotein.",
author = "Lal, {Renu B.} and Rudolph, {Donna L.} and Kaplan, {Jonathan E.} and Brian Hjelle and Levine, {Paul H.} and Coligan, {John E.} and Viscidi, {Raphael P}",
year = "1992",
doi = "10.1016/0042-6822(92)90081-Y",
language = "English (US)",
volume = "186",
pages = "274--279",
journal = "Virology",
issn = "0042-6822",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Identification of immunodominant epitopes in envelope glycoprotein of human T Lymphotropic virus type II

AU - Lal, Renu B.

AU - Rudolph, Donna L.

AU - Kaplan, Jonathan E.

AU - Hjelle, Brian

AU - Levine, Paul H.

AU - Coligan, John E.

AU - Viscidi, Raphael P

PY - 1992

Y1 - 1992

N2 - A series of synthetic peptides derived from the envelope glycoprotein of human T lymphotropic virus type II (HTLV-II) was used in an enzyme immunoassay to determine the immunodominant epitopes of envelope glycoprotein. Of the 11 synthetic peptides spanning the external glycoprotein of HTLV-II (gp52) and the 3 from the transmembrane protein (gp21), 3 peptides from gp52 (termed Env-2085-102. Env-20-209, and Env-20173-256) reacted with most of the polymerase chain reaction-confirmed HTLV-II specimens (83, 95, and 76%, respectively); all other peptides reacted minimally with these specimens. Env-20173-209 reacted with a greater percentage (91 to 100%) of specimens from different risk groups, including intravenous drug users (n = 30), North American Indians (n = 13), Guaymi Indians from Panama (n = 22), and routine U.S. blood donors (n = 34), when compared with Env-2085-102 (73 to 100%) or Env-203219-256 (68 to 83%). Furthermore, Env-2085-102 and Env-202172-209 had some reactivity (8-25%) with serafrom HTLV-I-infected individuals, whereas Env-20219-256 reacted with 58% of HTLV-I specimens. We conclude that peptides Env-2085-102 and Env-202173-209 represent the type-specific immunodominant epitopes of HTLV-II external glycoprotein.

AB - A series of synthetic peptides derived from the envelope glycoprotein of human T lymphotropic virus type II (HTLV-II) was used in an enzyme immunoassay to determine the immunodominant epitopes of envelope glycoprotein. Of the 11 synthetic peptides spanning the external glycoprotein of HTLV-II (gp52) and the 3 from the transmembrane protein (gp21), 3 peptides from gp52 (termed Env-2085-102. Env-20-209, and Env-20173-256) reacted with most of the polymerase chain reaction-confirmed HTLV-II specimens (83, 95, and 76%, respectively); all other peptides reacted minimally with these specimens. Env-20173-209 reacted with a greater percentage (91 to 100%) of specimens from different risk groups, including intravenous drug users (n = 30), North American Indians (n = 13), Guaymi Indians from Panama (n = 22), and routine U.S. blood donors (n = 34), when compared with Env-2085-102 (73 to 100%) or Env-203219-256 (68 to 83%). Furthermore, Env-2085-102 and Env-202172-209 had some reactivity (8-25%) with serafrom HTLV-I-infected individuals, whereas Env-20219-256 reacted with 58% of HTLV-I specimens. We conclude that peptides Env-2085-102 and Env-202173-209 represent the type-specific immunodominant epitopes of HTLV-II external glycoprotein.

UR - http://www.scopus.com/inward/record.url?scp=0026537115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026537115&partnerID=8YFLogxK

U2 - 10.1016/0042-6822(92)90081-Y

DO - 10.1016/0042-6822(92)90081-Y

M3 - Article

VL - 186

SP - 274

EP - 279

JO - Virology

JF - Virology

SN - 0042-6822

IS - 1

ER -